The Ryan White ADAP program—the most important source of US reimbursement for HIV drugs—is hurting: http://www.nytimes.com/2010/07/01/us/01aidsdrugs.html When government subsidies fall short, drug companies such as GILD have to make the slack (#msg-50936381).